Linked Life Data

19654406

Source:http://linkedlifedata.com/resource/pubmed/id/19654406

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2009-10-30
pubmed:abstractText
Tumor cell-derived heat shock proteins are used as vaccines for immunotherapy of cancer patients. However, current approaches require the generation of custom-made products and are clinically ineffective. To improve the applicability of heat shock protein-based immunotherapy in cancers and to enhance clinical efficacy, we explored combinational treatments in a myeloma setting using pooled heterogeneous or allogeneic myeloma cell line-derived glycoprotein 96 (gp96) as universal vaccines, and clearly demonstrated that pooled but not single gp96 from heterogeneous or allogeneic myeloma cell lines was as effective as autologous gp96 in protecting mice from tumor challenge and rechallenge and in treating established myeloma. We showed that interferon gamma and CD4+ and CD8+ T cells were required for gp96-induced antimyeloma responses and that pooled gp96 induced broader immune responses that protected mice from developing different myeloma. Furthermore, pooled gp96 plus CpG in combination with anti-B7H1 or anti-interleukin-10 monoclonal antibodies were effective in treating mice with large tumor burdens. Thus, this study strongly suggests that pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines from autologous tumors for immunotherapy and induce immune responses against broader tumor antigens that may protect against tumor recurrence and development of unrelated tumors in vaccinated myeloma patients.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
29
pubmed:volume
114
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3880-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19654406-Animals, pubmed-meshheading:19654406-Antibodies, Monoclonal, pubmed-meshheading:19654406-CD4-Positive T-Lymphocytes, pubmed-meshheading:19654406-CD8-Positive T-Lymphocytes, pubmed-meshheading:19654406-Cancer Vaccines, pubmed-meshheading:19654406-Cell Line, Tumor, pubmed-meshheading:19654406-Heat-Shock Proteins, pubmed-meshheading:19654406-Humans, pubmed-meshheading:19654406-Immunotherapy, pubmed-meshheading:19654406-Inducible T-Cell Co-Stimulator Ligand, pubmed-meshheading:19654406-Interferon-gamma, pubmed-meshheading:19654406-Interleukin-10, pubmed-meshheading:19654406-Mice, pubmed-meshheading:19654406-Mice, Inbred BALB C, pubmed-meshheading:19654406-Mice, Knockout, pubmed-meshheading:19654406-Multiple Myeloma, pubmed-meshheading:19654406-Neoplasm Proteins, pubmed-meshheading:19654406-Proteins
pubmed:year
2009
pubmed:articleTitle
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
pubmed:affiliation
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural